Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

50.200
+4.60010.09%
Volume:13.48M
Turnover:655.49M
Market Cap:333.18B
PE:36.41
High:50.400
Open:46.080
Low:45.380
Close:45.600
52wk High:94.869
52wk Low:43.020
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:5.00
T/O Rate:5.22%
Dividend:0.23
Dividend Rate:0.47%
EPS(LYR):1.379
ROE:12.46%
ROA:7.02%
PB:4.42
PE(LYR):36.41
PS:9.10

Loading ...

Hong Kong Stocks Close Higher as Property Stimulus Fails to Enthuse; Pharma Emerges as Safe Haven

Stock News
·
Yesterday

Daiwa: Hengrui Pharma (01276) Reaches Licensing Deal with Novo Nordisk for HRS-1596; Total Transaction Value and Upfront Payment Both Attractive

Stock News
·
Yesterday

Morgan Stanley Maintains Overweight Rating on Hengrui Pharma (01276) with HK$82 Target Price

Stock News
·
Yesterday

AI Drug Discovery Sector Heats Up: ChinaAMC Hang Seng Biotech (03069) Rises Over 4% Intraday, ChinaAMC Innovative Drugs (03525) Gains Over 3% in Afternoon Session

Stock News
·
Yesterday

HK Movers | Pharma Stocks Jump With CanSino Biologics up 19%, Joinn Laboratories up 17%

Tiger Newspress
·
Yesterday

Movement Alert|HENGRUI PHARMA Rises 3.33% in Regular Trading, Novo Nordisk Licensing Deal Worth Up to $2.6 Billion Continues to Fuel Rally

Market Focus
·
Yesterday

Hong Kong Stock Connect Innovative Drug Sector Defies Market Downturn as Top Pharmaceutical Firm Enters with US$2 Billion, Akeso Surges 15.54%, Hengrui Pharma Secures US$2.6 Billion BD Deal

Deep News
·
Sep 29

Novo Nordisk Strikes Second Licensing Deal Since Frosty Capital-Markets Day

Dow Jones
·
Sep 29

HENGRUI PHARMA: BlackRock, Inc. Disposes of Shares, Long Position Falls to 6.96%

HK Disclosure
·
Sep 29

Hengrui Pharma Licenses Oral GLP-1/GIP Weight-Loss Drug to Novo Nordisk in Deal Worth Up to $2.6 Billion

Deep News
·
Sep 29

China's Hengrui Inks up to $2.6 Billion Deal with Novo Nordisk for Obesity Drug

Reuters
·
Sep 29

Hengrui Pharma and Novo Nordisk Sign Licensing Agreement for HRS-1596 Project

Stock News
·
Sep 29

Hengrui Pharma Inks Up to USD 2.60 Billion Global Licence Deal with Novo Nordisk for Oral GLP-1/GIP Agonist HRS-1596

Bulletin Express
·
Sep 29

Jiangsu Hengrui Pharmaceuticals - Entering into License Agreement for Hrs-1596 with Novo Nordisk a/S

THOMSON REUTERS
·
Sep 29

Jiangsu Hengrui Pharmaceuticals - Potential Total Value of Agreement up to $2.6 Bln Contingent on Achievement of Applicable Development, Others

THOMSON REUTERS
·
Sep 29

Jiangsu Hengrui Pharmaceuticals - Dedal Includes $300 Mln Upfront Payment

THOMSON REUTERS
·
Sep 29

Jiangsu Hengrui Pharmaceuticals - Co Also Eligible to Receive Royalties Based on Net Sales of Hrs-1596 Within Licensed Territory

THOMSON REUTERS
·
Sep 29

Movement Alert|HENGRUI PHARMA Rises 3.57% in Regular Trading, Multiple Global Institutions Accumulate Shares Amid Accelerated Drug Approvals

Market Focus
·
Sep 29

Blackrock's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 7.32%, Says HKEX

Reuters
·
Sep 25

UBS Group Ag's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 5.23% on Sept 21 from 4.43% - HKEX

THOMSON REUTERS
·
Sep 25